Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776295 | 0.85 | CLK2 (0.41) | RPS6KA3RPS6KA2MCL1CACNA1HCACNA1I | |
| SCHEMBL16776187 | 0.82 | RPS6KA3 (0.41) | RPS6KA3RPS6KA2CACNA1HCACNA1ICACNA1G | |
| SCHEMBL16775993 | 0.82 | ABL1 (0.43) | RPS6KA3RPS6KA2HTR1ADRD2MAPT | |
| SCHEMBL16775982 | 0.80 | CACNA1G (0.43) | RPS6KA3RPS6KA2CACNA1HCACNA1ICACNA1G | |
| SCHEMBL16776218 | 0.79 | RPS6KA3 (0.42) | RPS6KA3RPS6KA2NAMPTMAPTCACNA1H | |
| SCHEMBL16776217 | 0.79 | NAMPT (0.45) | RPS6KA3RPS6KA2MCL1NAMPTMAPT | |
| SCHEMBL16776253 | 0.78 | RPS6KA3 (0.42) | RPS6KA3RPS6KA2NAMPTMAPTCACNA1H | |
| SCHEMBL17618754 | 0.77 | HTR2C (0.39) | MCL1HTR1ADRD2RIPK2NAMPT | |
| SCHEMBL16776270 | 0.77 | ABL1 (0.42) | RPS6KA3RPS6KA2HTR1ADRD2MAPT | |
| SCHEMBL16776243 | 0.77 | RPS6KA3 (0.39) | RPS6KA3RPS6KA2MAPTCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RPS6KA3 2368/4885RPS6KA2 2318/4885MCL1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.